nevirapine has been researched along with Hepatitis B in 15 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Hepatitis B: INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Widespread use of lamivudine in antiretroviral therapy may lead to hepatitis B virus resistance in HIV-HBV coinfected patients from endemic settings where tenofovir is not readily available." | 9.15 | HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya. ( Cent, A; Chung, MH; Cook, L; Jerome, KR; John-Stewart, G; Kim, HN; Lule, G; Morrow, RA; Richardson, B; Scott, J; Tapia, K, 2011) |
| "Coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) in HIV-infected patients receiving a commonly used nevirapine-based antiretroviral therapy is a major concern for African clinicians owing to its high prevalence, the infrequent testing and treatment of viral hepatitis, and the impact of liver disease on the tolerability and effectiveness of anti-HIV treatment." | 7.76 | Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. ( Bourgeois, A; Calmy, A; Ciaffi, L; Delaporte, E; Ducos, J; Gwet, H; Kouanfack, C; Koulla-Shiro, S; Laurent, C; Mbougua, JB; Molinari, N; Mpoudi-Ngolé, E, 2010) |
| "Widespread use of lamivudine in antiretroviral therapy may lead to hepatitis B virus resistance in HIV-HBV coinfected patients from endemic settings where tenofovir is not readily available." | 5.15 | HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya. ( Cent, A; Chung, MH; Cook, L; Jerome, KR; John-Stewart, G; Kim, HN; Lule, G; Morrow, RA; Richardson, B; Scott, J; Tapia, K, 2011) |
| "It has been proposed that hepatitis B virus (HBV) sub-genotype A1 infections have mild outcomes and a low risk of drug-resistance among patients infected with human immunodeficiency virus (HIV) receiving lamivudine-containing antiretroviral therapy (ART) without tenofovir in Africa." | 3.80 | Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi. ( Aoudjane, S; Beloukas, A; Chaponda, M; Geretti, AM; González Del Castillo, AA; Hopkins, M; Khoo, S; Noguera, M; O'Connor, J; van Oosterhout, JJ, 2014) |
| "Coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) in HIV-infected patients receiving a commonly used nevirapine-based antiretroviral therapy is a major concern for African clinicians owing to its high prevalence, the infrequent testing and treatment of viral hepatitis, and the impact of liver disease on the tolerability and effectiveness of anti-HIV treatment." | 3.76 | Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. ( Bourgeois, A; Calmy, A; Ciaffi, L; Delaporte, E; Ducos, J; Gwet, H; Kouanfack, C; Koulla-Shiro, S; Laurent, C; Mbougua, JB; Molinari, N; Mpoudi-Ngolé, E, 2010) |
| " Risk factors were higher baseline alanine aminotransferase levels, chronic hepatitis B or C virus infection, antiretroviral therapy-naive patients undergoing their first HAART regimen, recent start of a regimen of nevirapine or high-dose ritonavir, and female sex." | 3.71 | Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. ( Jurriaans, S; Lange, JM; Weel, J; Weverling, GJ; Wit, FW, 2002) |
| " Multivariate logistic regression was used to test independent association of CD4 and hepatitis C virus (HCV) infection related to the outcome of toxic effects of NVP." | 1.33 | Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. ( Calvet, GA; Cruz, ML; D'Ippolito, MM; João, EC; Matos, HJ; Menezes, JA; Salgado, LA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bhattacharya, D | 1 |
| Guo, R | 1 |
| Tseng, CH | 1 |
| Emel, L | 1 |
| Sun, R | 1 |
| Chiu, SH | 1 |
| Stranix-Chibanda, L | 1 |
| Chipato, T | 1 |
| Mohtashemi, NZ | 1 |
| Kintu, K | 1 |
| Manji, KP | 1 |
| Moodley, D | 1 |
| Thio, CL | 1 |
| Maldonado, Y | 1 |
| Currier, JS | 1 |
| Su, S | 1 |
| Fairley, CK | 1 |
| Sasadeusz, J | 1 |
| He, J | 1 |
| Wei, X | 1 |
| Zeng, H | 1 |
| Jing, J | 1 |
| Mao, L | 1 |
| Chen, X | 1 |
| Zhang, L | 1 |
| Torimiro, JN | 1 |
| Nanfack, A | 1 |
| Takang, W | 1 |
| Keou, CK | 1 |
| Joyce, AN | 1 |
| Njefi, K | 1 |
| Agyingi, K | 1 |
| Domkam, I | 1 |
| Takou, D | 1 |
| Moudourou, S | 1 |
| Sosso, S | 1 |
| Mbu, RE | 1 |
| van Griensven, J | 1 |
| Phirum, L | 1 |
| Choun, K | 1 |
| Thai, S | 1 |
| De Weggheleire, A | 1 |
| Lynen, L | 1 |
| Andreotti, M | 1 |
| Pirillo, MF | 1 |
| Liotta, G | 1 |
| Jere, H | 1 |
| Maulidi, M | 1 |
| Sagno, JB | 1 |
| Luhanga, R | 1 |
| Amici, R | 1 |
| Mancini, MG | 1 |
| Gennaro, E | 1 |
| Marazzi, MC | 1 |
| Vella, S | 1 |
| Giuliano, M | 1 |
| Palombi, L | 1 |
| Mancinelli, S | 1 |
| Aoudjane, S | 1 |
| Chaponda, M | 1 |
| González Del Castillo, AA | 1 |
| O'Connor, J | 1 |
| Noguera, M | 1 |
| Beloukas, A | 1 |
| Hopkins, M | 1 |
| Khoo, S | 1 |
| van Oosterhout, JJ | 1 |
| Geretti, AM | 1 |
| Mbougua, JB | 1 |
| Laurent, C | 1 |
| Kouanfack, C | 1 |
| Bourgeois, A | 1 |
| Ciaffi, L | 1 |
| Calmy, A | 1 |
| Gwet, H | 1 |
| Koulla-Shiro, S | 1 |
| Ducos, J | 1 |
| Mpoudi-Ngolé, E | 1 |
| Molinari, N | 1 |
| Delaporte, E | 1 |
| Kim, HN | 1 |
| Scott, J | 1 |
| Cent, A | 1 |
| Cook, L | 1 |
| Morrow, RA | 1 |
| Richardson, B | 1 |
| Tapia, K | 1 |
| Jerome, KR | 1 |
| Lule, G | 1 |
| John-Stewart, G | 1 |
| Chung, MH | 1 |
| Rosso, R | 1 |
| Rossotti, R | 1 |
| Di Biagio, A | 1 |
| Nicolini, L | 1 |
| Adorni, F | 1 |
| Orani, A | 1 |
| Viscoli, C | 1 |
| Pulido, F | 1 |
| Torralba, M | 1 |
| Law, WP | 1 |
| Dore, GJ | 1 |
| Duncombe, CJ | 1 |
| Mahanontharit, A | 1 |
| Boyd, MA | 1 |
| Ruxrungtham, K | 1 |
| Lange, JM | 2 |
| Phanuphak, P | 1 |
| Cooper, DA | 1 |
| Almond, LM | 1 |
| Boffito, M | 1 |
| Hoggard, PG | 1 |
| Bonora, S | 1 |
| Raiteri, R | 1 |
| Reynolds, HE | 1 |
| Garazzino, S | 1 |
| Sinicco, A | 1 |
| Khoo, SH | 1 |
| Back, DJ | 1 |
| Di Perri, G | 1 |
| João, EC | 1 |
| Calvet, GA | 1 |
| Menezes, JA | 1 |
| D'Ippolito, MM | 1 |
| Cruz, ML | 1 |
| Salgado, LA | 1 |
| Matos, HJ | 1 |
| Sulkowski, MS | 1 |
| Thomas, DL | 1 |
| Mehta, SH | 1 |
| Chaisson, RE | 1 |
| Moore, RD | 1 |
| Wit, FW | 1 |
| Weverling, GJ | 1 |
| Weel, J | 1 |
| Jurriaans, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding[NCT00074412] | Phase 3 | 2,026 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Long-term Follow-up Study for HIV-infected Individuals Who Have Participated in HIV-NAT Study Protocols[NCT00411983] | 10,000 participants (Anticipated) | Observational | 2002-11-30 | Recruiting | |||
| Multicenter, Pilot Study of Telbivudine (LdT) Anti-HBV Treatment Prior to the Initiation of Highly Active Antiretroviral Therapy Containing Lamivudine in Subjects Coinfected With HBV and HIV[NCT00051090] | 0 participants (Actual) | Interventional | Withdrawn | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For those infants who were randomized at 6 weeks and who initiated study drug we looked at the frequency and severity of adverse reactions through 18 months of study. The severity of all AEs was graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. The term severity is described as the intensity grade or level for specific event (i.e. mild, moderate, severe, or life-threatening). Severity is not the same as seriousness. (NCT00074412)
Timeframe: 6 weeks through 18 months
| Intervention | Number of Adverse Events (Number) | ||||
|---|---|---|---|---|---|
| Death | Life-Threatening | Severe | Moderate | Mild | |
| Nevirapine | 26 | 87 | 375 | 694 | 832 |
| Placebo | 30 | 87 | 332 | 677 | 838 |
(NCT00074412)
Timeframe: At Month 6
| Intervention | participants (Number) | |
|---|---|---|
| # of HIV infections at 6 months | # of Infants at risk for HIV infection at 6 months | |
| Nevirapine | 8 | 700 |
| Placebo | 18 | 699 |
(NCT00074412)
Timeframe: At Month 18
| Intervention | participants (Number) | |
|---|---|---|
| # Infant Deaths at 18 months | # Infants at risk of death at 18 months | |
| Nevirapine | 26 | 678 |
| Placebo | 30 | 684 |
(NCT00074412)
Timeframe: At Months 6 and 18
| Intervention | participants (Number) | |
|---|---|---|
| Number of Infants Alive and HIV-free at 6 months | Number of Infants Alive and HIV-free at 18 months | |
| Nevirapine | 689 | 629 |
| Placebo | 683 | 616 |
(NCT00074412)
Timeframe: At Month 18
| Intervention | participants (Number) | |
|---|---|---|
| # of infants with HIV infection at 18 months | # of infants @ risk for HIV infection at 18 months | |
| Nevirapine | 16 | 664 |
| Placebo | 23 | 663 |
1 review available for nevirapine and Hepatitis B
| Article | Year |
|---|---|
NNRTI hepatotoxicity: efavirenz versus nevirapine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Hepat | 2002 |
2 trials available for nevirapine and Hepatitis B
| Article | Year |
|---|---|
Maternal HBV Viremia and Association With Adverse Infant Outcomes in Women Living With HIV and HBV.
Topics: Anti-HIV Agents; Birth Weight; Coinfection; Double-Blind Method; Female; Hepatitis B; Hepatitis B vi | 2021 |
HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Drug Resistance, Viral; F | 2011 |
12 other studies available for nevirapine and Hepatitis B
| Article | Year |
|---|---|
HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induce | 2018 |
Rates of HBV, HCV, HDV and HIV type 1 among pregnant women and HIV type 1 drug resistance-associated mutations in breastfeeding women on antiretroviral therapy.
Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Cameroon; Coinfection; Drug Resistance, Viral; F | 2018 |
Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cambodia; CD4 Lymphocyte Count; Coinfection; C | 2014 |
The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; Hepatitis B; He | 2014 |
Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; | 2014 |
Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
Topics: Adult; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Coho | 2010 |
Nevirapine-based regimens in routine clinical settings: results from a large Italian cohort of HIV-1 infected adults.
Topics: Adult; Age Factors; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol; Cohort Studies; Databa | 2011 |
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclop | 2003 |
The relationship between nevirapine plasma concentrations and abnormal liver function tests.
Topics: Alanine Transaminase; Anti-HIV Agents; Cross-Sectional Studies; Ethnicity; Female; gamma-Glutamyltra | 2004 |
Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cholestasis; Cohort Studies; Female; Hepatitis B; Hepa | 2006 |
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspart | 2002 |
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Dr | 2002 |